Src and focal adhesion kinase as therapeutic targets in cancer

被引：148

作者：

Brunton, Valerie G. ^{[1
]}

Frame, Margaret C. ^{[1
]}

机构：

[1] Univ Edinburgh, Div Canc Biol, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland

来源：

CURRENT OPINION IN PHARMACOLOGY | 2008年 / 8卷 / 04期

关键词：

D O I：

10.1016/j.coph.2008.06.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Over the past few years small molecule inhibitors of both Src family kinases and focal adhesion kinase (FAK) have entered clinical studies for the treatment of solid tumours. These adhesion-linked kinases are involved in a number of pathways that have impact on the behaviour of tumour cells and the challenge is now, how to take these forward in the clinical setting.

引用

页码：427 / 432

页数：6

共 58 条

[31] Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer [J].

Maurer, Gabriele D. ;

Leupold, Joerg H. ;

Schewe, Denis M. ;

Biller, Tobias ;

Kates, Ronald E. ;

Hornung, Hans-Martin ;

Lau-Werner, Ulla ;

Post, Stefan ;

Allgayer, Heike .

CLINICAL CANCER RESEARCH, 2007, 13 (04) :1123-1132

[32] Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression [J].

McLean, GW ;

Komiyama, NH ;

Serrels, B ;

Asano, H ;

Reynolds, L ;

Conti, F ;

Hodivala-Dilke, K ;

Metzger, D ;

Chambon, P ;

Grant, SGN ;

Frame, MC .

GENES & DEVELOPMENT, 2004, 18 (24) :2998-3003

[33] The role of focal-adhesion kinase in cancer. A ew therapeutic opportunity [J].

McLean, GW ;

Carragher, NO ;

Avizienyte, E ;

Evans, J ;

Brunton, VG ;

Frame, MC .

NATURE REVIEWS CANCER, 2005, 5 (07) :505-515

[34] Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells [J].

Nam, S ;

Kim, DW ;

Cheng, JQ ;

Zhang, SM ;

Lee, JH ;

Buettner, R ;

Mirosevich, J ;

Lee, FY ;

Jove, R .

CANCER RESEARCH, 2005, 65 (20) :9185-9189

[35] Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo [2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro.: Involvement of ERK1/2 pathway [J].

Recchia, I ;

Rucci, N ;

Funari, A ;

Migliaccio, S ;

Taranta, A ;

Longo, M ;

Kneissel, M ;

Susa, M ;

Fabbro, D ;

Teti, A .

BONE, 2004, 34 (01) :65-79

[36] Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271 [J].

Roberts, Walter Gregory ;

Ung, Ethan ;

Whalen, Pamela ;

Cooper, Beth ;

Hulford, Catherine ;

Autry, Christofer ;

Richter, Daniel ;

Emerson, Earling ;

Lin, Jing ;

Kath, John ;

Coleman, Kevin ;

Yao, Lili ;

Martinez-Alsina, Luis ;

Lorenzen, Marianne ;

Berliner, Martin ;

Luzzio, Michael ;

Patel, Nandini ;

Schmitt, Erika ;

LaGreca, Susan ;

Jani, Jitesh ;

Wessel, Matt ;

Marr, Eric ;

Griffor, Matt ;

Vajdos, Felix .

CANCER RESEARCH, 2008, 68 (06) :1935-1944

[37] Mechanisms of disease: Mechanisms of bone metastasis [J].

Roodman, GD .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1655-1664

[38] Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib [J].

Serrels, Alan ;

Macpherson, Iain R. J. ;

Evans, T. R. Jeffry ;

Lee, Francis Y. ;

Clark, Edwin A. ;

Sansom, Owen J. ;

Ashton, Gabrielle H. ;

Frame, Margaret C. ;

Brunton, Valerie G. .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (12) :3014-3022

[39]

Shakespeare WC, 2003, CURR OPIN DRUG DISC, V6, P729

[40]

Sieg DJ, 1999, J CELL SCI, V112, P2677

← 1 2 3 4 5 6 →